The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026). 6710
What this version reported
The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.↗↗↗↗
Reader guide in this version
Key takeaway
Tirzepatide is a lab-made peptide that activates the receptors for two gut hormones, GIP and GLP-1, and is the active ingredient in Mounjaro and Zepbound.1,2 It is FDA-approved: Mounjaro for adults with type 2 diabetes, and Zepbound for long-term weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity.1,2 In August 2026 FDA added a use for Mounjaro, lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk, based on a cardiovascular outcomes trial.6 FDA says compounded and other unapproved tirzepatide products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed.10
At a glance
- What it is
- A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.1
- FDA status
- FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.1,4,5
- Human evidence
- Large randomized, placebo-controlled trials described in the Zepbound label, and a cardiovascular outcomes trial that FDA cites as the basis for a 2026 Mounjaro approval.1,6
- Evidence strength
- Large randomized human trials
What is tirzepatide?
Tirzepatide is a lab-made peptide that acts on the receptors for two hormones released by the gut: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).1
Drugs@FDA lists it as the active ingredient of two Eli Lilly brands: Mounjaro and Zepbound.4,5
How does tirzepatide work?
The Zepbound label states that tirzepatide binds to and activates both the GIP and GLP-1 receptors, and that GLP-1 is a physiological regulator of appetite and calorie intake.1
According to the label, nonclinical studies suggest GIP may further contribute to regulating food intake, and animal studies show tirzepatide reaching and activating brain regions involved in appetite.1
What do human studies show?
The Zepbound label describes two 72-week randomized, placebo-controlled weight trials: one of 2,539 adults without type 2 diabetes and one of 938 adults with type 2 diabetes. It reports a statistically significant reduction in body weight compared with placebo in both.1
The label notes that body weight at week 72 was missing for some participants, up to 21.6% in one placebo group, and that missing values were imputed.1
Two 52-week trials in 469 adults with obesity and moderate to severe obstructive sleep apnea found a statistically significant reduction in the apnea-hypopnea index compared with placebo, according to the label.1
FDA’s August 2026 letters describe SURPASS-CVOT, a trial comparing tirzepatide with dulaglutide on major adverse cardiovascular events in adults with type 2 diabetes, conducted in adults with established cardiovascular disease.6,7
What the evidence base contains
- Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.1
- Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.1
- Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.1
- Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.6,7
Evidence-strength label: Large randomized human trials. How this label is assigned
Is tirzepatide FDA-approved?
Yes. Drugs@FDA records list Mounjaro’s original approval on May 13, 2022 and Zepbound’s on November 8, 2023.4,5
FDA’s November 2023 announcement describes Mounjaro as approved, along with diet and exercise, to improve blood sugar in adults with type 2 diabetes.2
The Zepbound label cited here (DailyMed SPL version 40, published September 2, 2026) states that Zepbound is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.1
On August 27, 2026, FDA approved a Mounjaro supplement adding a new indication: reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with type 2 diabetes who are at high risk for them. The same letter records label changes to the warning on diabetic eye complications, based on SURPASS-CVOT.6
A Zepbound supplement effective August 26, 2026 added the SURPASS-CVOT results to the Zepbound prescribing information, with the same eye-complication warning change, according to FDA’s corrected approval letter. It did not add a cardiovascular indication for Zepbound, and the Zepbound label version cited here does not yet include that change.1,7
The Zepbound label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1
Other warnings in the label cover severe gastrointestinal reactions, kidney injury from fluid loss, gallbladder disease, acute pancreatitis, allergic reactions, low blood sugar, diabetic eye complications in people with type 2 diabetes and aspiration during anesthesia or deep sedation.1
In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines.8
FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, describes fraudulent compounded tirzepatide whose labels name pharmacies that do not exist or did not make the product.10
The same page reports more than 730 adverse-event reports associated with compounded tirzepatide received as of May 31, 2026, and describes products falsely labeled as being for research purposes or not for human consumption.10
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.9
Timeline
- FDA approves Mounjaro, the first tirzepatide product, according to Drugs@FDA.4
- FDA approves Zepbound for chronic weight management.2,5
- FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.8
- FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9
- FDA approves a Zepbound label update adding SURPASS-CVOT results, according to its corrected approval letter.7
- FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.6
- DailyMed publishes the Zepbound label version cited on this page.1
- FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10
What is still unknown?
Whether tirzepatide causes thyroid C-cell tumors in humans, which the label says has not been determined.1
Whether a cardiovascular benefit extends to people without type 2 diabetes: the new cardiovascular indication described in FDA’s letter covers adults with type 2 diabetes at high cardiovascular risk.6
What is in compounded, counterfeit or so-called research products, which FDA says it does not review before they reach the market.10
Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.9
Sources for this version
- 1ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 2FDA approves tirzepatide for chronic weight management ↗
U.S. Food and Drug Administration · Official source · Source checked July 22, 2026
- 3Tirzepatide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
- 4Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 7Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 9FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 10FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026